Clinical trials: Neoadjuvant Therapy in Rectal Cancer
Rectum Cancer
MRI Split Scar Sign as a Predictor to Complete Pathologic Response After Neoadjuvant Chemoradiation in Rectal Cancer
Patients with middle or low rectal cancer who receive neoadjuvant chemoradiation and achieve complete clinical response while their pelvic MRI have split scar sign are included.
- Trial name
- NCT04745091
- Testing
- total mesorectal excision
- Volunteers
- 20 people
- Sponsor
- Alexandria University
Liver Metastases, Recurrent Colon Cancer
Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer
Drugs used in chemotherapy, such as capecitabine and oxaliplatin, use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
- Trial name
- NCT00070265
- Testing
- oxaliplatin, capecitabine, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Neoplasm
Validate the Dosimetric Parameters That Correlate With Acute Hematologic Toxicity (HT) in Patients With Rectal Cancer
The purpose of this study is to validate the dosimetric parameters that correlate with acute hematologic toxicity (HT) in patients with rectal cancer treated with neoadjuvant chemoradiotherapy.
- Trial name
- NCT02630056
- Volunteers
- 90 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Cancer
Expression of Molecular Markers Before and After Neo-adjuvant Chemoradiotherapy in Rectal Cancer
The purpose of this study is to determine whether markers on tumor tissue may be an indicator for good response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
- Trial name
- NCT00835055
- Where
- Switzerland
- Sponsor
- St. Claraspital AG
Rectal Neoplasms
Prediction of Response to Neoadjuvant Therapy in Rectal Cancer
The purpose of this study is to determine whether 18F-FDG-PET-CT and texture analysis of MRI performed 9 weeks after Neoadjuvant Chemo-radiotherapy in patients with locally advanced rectal cancer has the ability to identify…
- Trial name
- PRENT-LARC (NCT02439086)
- Testing
- PET-CT Scan
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Colchester General Hospital
Locally Advanced Rectal Cancer
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer
The study evaluates the addition of immunotherapy of PD-1 antibody in neoadjuvant chemoradiotherapy in microsatellite stability-high (MSI-H) locally advanced rectal cancer (LARC).
- Trial name
- NCT04411524
- Testing
- PD-1 antibody, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Rectal Cancer, Oncology
Outcomes of Neoadjuvant Therapy for Rectal Cancer in a Tertiary Asian Institute
This is a retrospective cohort study that aims to evaluate the correlation of magnetic resonance tumour regression grade (mrTRG) and pathological TRG (pTRG) of locally advanced rectal cancer after neoadjuvant long course…
- Trial name
- NCT05607186
- Testing
- neoadjuvant long course chemoradiotherapy
- Volunteers
- 59 people
- Sponsor
- Singapore General Hospital
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
This single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin and capecitabine (XELOX) in patients with…
- Trial name
- NCT00700570
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin
- Where
- 6 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Rectal Cancer, Neoadjuvant Therapy
Interval Between Neoadjuvant Therapy and Surgery in the Treatment of Locally Advanced Rectal Cancer (CRONOS)
The investigators evaluate the response of rectal cancer to neoadjuvant therapy and classify the response according to specific periods of time after the end of neoadjuvant treatment.
- Trial name
- CRONOS (NCT04717947)
- Testing
- Interval between NAT and surgery
- Where
- Spain
- Volunteers
- 911 people
- Sponsor
- Hospital Clinic of Barcelona
Rectal Cancer Stage II, Rectal Cancer Stage III
Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Rectal cancer patients who received neoadjuvant chemoradiotherapy in Peking University Third Hospital in 2021 are divided into acute myelosuppression group, chronic myelosuppression group and normal group.
- Trial name
- NCT04970498
- Testing
- MRI, blood routine test
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University Third Hospital
Locally Advanced Rectal Cancer (LARC)
AI-Based Prediction of Pathological Response in Rectal Cancer Patients Receiving Total Neoadjuvant Therapy
This study aims to better understand how body composition, inflammation, and nutrition affect how rectal cancer responds to treatment.
- Trial name
- CINR-AI (NCT07049627)
- Testing
- Total Neoadjuvant Therapy (TNT)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 93 people
- Sponsor
- Ankara Etlik City Hospital
Locally Advanced Rectal Carcinoma
Assessment of Efficacy of Neoadjuvant Therapy in Locally Advanced Rectal Cancer
This study analyzed the efficacy differences between neoadjuvant therapy and direct surgical treatment in patients with locally advanced rectal cancer in the real world.
- Trial name
- NCT06314737
- Volunteers
- 3,515 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer
Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy
A novel evaluation model for identifying complete response following neoadjuvant immune checkpoint inhibitor therapy therapy in patients with dMMR colon cancer was developed to validated its efficacy in two independent cohorts…
- Trial name
- NCT06980350
- Testing
- PD-1 Inhibitors
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
The goal of this observational study is to learn about the amide proton transfer-weighted imaging for rectal cancer response assessment after neoadjuvant therapy.
- Trial name
- NCT06719414
- Where
- 2 sites in China
- Volunteers
- 320 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer, Neoadjuvant Systemic Therapy
Survival Benefit of Primary Tumour Resection Compared to Systemic Therapy Alone in Stage IV Colorectal Cancer Patients
About 20-25 percent of all colorectal cancer patients are diagnosed with International Union Against Cancer (UICC) stage IV disease. The benefit of primary tumor resection in the palliative context is therefore of high concern.
- Trial name
- SurvSysT (NCT06326619)
- Testing
- Primary tumor resection, Systemic Therapy
- Volunteers
- 480 people
- Sponsor
- Medizinische Hochschule Brandenburg Theodor Fontane
Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent
[68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy
This diagnostic study investigates the value of 68Ga-NOTA-GZP PET imaging in predicting and evaluating immunotherapy response in malignant tumors by enrolling pathologically confirmed patients scheduled for immunotherapy and…
- Conditions
- Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, Colorectal Cancer Screening
- Trial name
- NCT06982053
- Testing
- Received 68Ga-NOTA-GZP PET scanning
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology